RxDoctor Payments Data

Jorge Busse, MD

Nephrology · Miami, FLNPI 1922091248

Payments from drug & device makers

$28,317in general payments, 2019–2025

Across 307 payments — averaging $92.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$13K
  • Otsuka America Pharmaceutical, Inc.$10K
  • AstraZeneca$793
  • Bayer$656
  • Travere Therapeutics, Inc.$597
  • Amgen$560
  • plus $3K from 19 others

What the payments were for

  • Speaking & faculty fees$20,85874%
  • Travel & lodging$870%
  • Food & beverage$7,28426%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,317 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$68,256
Medicare patients
207
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CrysvitaBurosumab-Twza15$344,939
FarxigaDapagliflozin Propanediol218$249,928
VeltassaPatiromer Calcium Sorbitex77$85,914
KerendiaFinerenone70$75,147
ProcritEpoetin Alfa107$69,889
JardianceEmpagliflozin45$57,419
Repatha SureclickEvolocumab66$43,192
EpogenEpoetin Alfa48$22,194
RetacritEpoetin Alfa-Epbx68$18,007
OzempicSemaglutide16$17,070
LokelmaSodium Zirconium Cyclosilicate18$16,108
AranespDarbepoetin Alfa In Polysorbat15$13,917
LivaloPitavastatin Calcium26$11,370
Bumetanide327$9,810
Ezetimibe494$8,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kyowa Kirin, Inc.Crysvita$70$344,93915 claims
AstraZenecaFarxiga, Lokelma$793$266,036236 claims
BayerKerendia$656$75,14770 claims
Boehringer IngelheimJardiance$217$57,41945 claims
AmgenEpogen, Aranesp$560$36,11163 claims
Novo NordiskOzempic$164$17,07016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →